开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R587

References36

[1]	Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association[J]. BMJ, 2020, 369: m997.
[2]	Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi:10.1016/j.diabres.2019.107843 URL
[3]	Li S, Nemeth I, Donnelly L, et al. Visit-to-visit HbA_1cvariability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes[J]. Diabetes Care, 2020, 43(2): 426-432. doi:10.2337/dc19-0823 URL
[4]	Virk SA, Donaghue KC, Cho YH, et al. Association between HbA_1cvariability and risk of microvascular com-plications in adolescents with type 1 diabetes[J]. J Clin Endocrinol Metab, 2016, 101(9): 3257-3263. doi:10.1210/jc.2015-3604 URL
[5]	Iuchi H, Sakamoto M, Matsutani D, et al. The durability of basal insulin affects day-to-day glycemic variability assessed by continuous glucose monitoring in type 2 diabetes patients[J]. Diabetes Technol Ther, 2017, 19(8): 457-462. doi:10.1089/dia.2017.0028 URL
[6]	Sun B, He F, Gao Y, et al. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes[J]. Endocrine, 2019, 64(3): 536-543. doi:10.1007/s12020-019-01893-1 URL
[7]	Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes[J]. Diabetes Care, 2015, 38(12): 2354-2369. doi:10.2337/dc15-1188 URL
[8]	Walker GS, Chen JY, Hopkinson H, et al. Structured education using dose adjustment for normal eating (DAFNE) reduces long-term HbA_1cand HbA_1cvariability[J]. Diabet Med, 2018, 35(6): 745-749. doi:10.1111/dme.13621 URL
[9]	Wadén J, Forsblom C, Thorn LM, et al. A_1cvariability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes[J]. Diabetes, 2009, 58(11): 2649-2655. doi:10.2337/db09-0693 URL
[10]	Shen Y, Dai D, Lu J, et al. Visit-to-visit variability of glycated albumin was associated with incidence or progression of lower extremity atherosclerotic disease[J]. Cardiovasc Diabetol, 2020, 19(1): 211. doi:10.1186/s12933-020-01187-1pmid:33302958
[11]	Wan EY, Fung CS, Fong DY, et al. Association of variability in hemoglobin A_1cwith cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Complications, 2016, 30(7): 1240-1247. doi:10.1016/j.jdiacomp.2016.05.024 URL
[12]	Zorena K. Anti-inflammatory therapy in diabetic retinopathy[J]. Mediators Inflamm, 2014, 2014: 947896.
[13]	Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment[J]. Dtsch Arztebl Int, 2010, 107(5): 75-83. doi:10.3238/arztebl.2010.0075pmid:20186318
[14]	Hermann JM, Hammes HP, Rami-Merhar B, et al. HbA_1cvariability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German/Austrian multicenter analysis on 35,891 patients[J]. PLoS One, 2014, 9(3): e91137. doi:10.1371/journal.pone.0091137 URL
[15]	Rosa LCGFD, Zajdenverg L, Souto DL, et al. HbA_1cvariability and long-term glycemic control are linked to diabetic retinopathy and glomerular filtration rate in patients with type 1 diabetes and multiethnic background[J]. J Diabetes Complications, 2019, 33(9): 610-615. doi:10.1016/j.jdiacomp.2019.05.022 URL
[16]	Penno G, Solini A, Bonora E, et al. HbA_1cvariability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes[J]. Diabetes Care, 2013, 36(8): 2301-2310. doi:10.2337/dc12-2264 URL
[17]	Foo V, Quah J, Cheung G, et al. HbA_1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics[J]. J Diabetes, 2017, 9(2): 200-207. doi:10.1111/1753-0407.12403 URL
[18]	Takao T, Suka M, Yanagisawa H, et al. Predictive ability of visit-to-visit variability in HbA_1cand systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes[J]. Diabetes Res Clin Pract, 2017, 128: 15-23. doi:10.1016/j.diabres.2017.03.027 URL
[19]	胡佳琪, 徐慧君, 刘超, 等. HbA_1c变异性的影响因素及其对2型糖尿病视网膜病变的作用[J]. 中华内分泌代谢杂志, 2020, 36(5): 381-386.
[20]	Ioannou K. Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis[J]. Hormones (Athens), 2017, 16(4): 351-361.
[21]	Li L, Jiang XG, Hu JY, et al. The association between interleukin-19 concentration and diabetic nephropathy[J]. BMC Nephrol, 2017, 18(1): 65. doi:10.1186/s12882-017-0488-7pmid:28201997
[22]	Furuichi K, Shimizu M, Hara A, et al. Diabetic nephropathy: a comparison of the clinical and pathological features between the CKD risk classification and the classification of diabetic nephropathy 2014 in Japan[J]. Intern Med, 2018, 57(23): 3345-3350. doi:10.2169/internalmedicine.1132-18 URL
[23]	Lin CC, Chen CC, Chen FN, et al. Risks of diabetic nephropathy with variation in hemoglobin A_1cand fasting plasma glucose[J]. Am J Med, 2013, 126(11): 1017.
[24]	Yun KJ, Kim HJ, Kim MK, et al. Risk factors for the development and progression of diabetic kidney disease in patients with type 2 diabetes mellitus and advanced diabetic retinopathy[J]. Diabetes Metab J, 2016, 40(6): 473-481. doi:10.4093/dmj.2016.40.6.473 URL
[25]	Dorajoo SR, Ng JSL, Goh JHF, et al. HbA_1cvariability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years[J]. Diabetes Res Clin Pract, 2017, 128: 32-39. doi:10.1016/j.diabres.2017.02.007 URL
[26]	Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies[J]. Diabetologia, 2000, 43(8): 957-973. pmid:10990072
[27]	Feldman EL, Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain[J]. Neuron, 2017, 93(6): 1296-1313. doi:S0896-6273(17)30089-2pmid:28334605
[28]	Su JB, Zhao LH, Zhang XL, et al. HbA_1cvariability and diabetic peripheral neuropathy in type 2 diabetic patients[J]. Cardiovasc Diabetol, 2018, 17(1): 47. doi:10.1186/s12933-018-0693-0 URL
[29]	Lai YR, Chiu WC, Huang CC, et al. HbA_1cvariability is strongly associated with the severity of peripheral neuropathy in patients with type 2 diabetes[J]. Front Neurosci, 2019, 13: 90. doi:10.3389/fnins.2019.00090 URL
[30]	Cardoso CRL, Leite NC, Moram CBM, et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2018, 17(1): 33. doi:10.1186/s12933-018-0677-0pmid:29477146
[31]	Teliti M, Cogni G, Sacchi L, et al. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients[J]. Diab Vasc Dis Res, 2018, 15(5): 424-432. doi:10.1177/1479164118780808 URL
[32]	Lai YR, Huang CC, Chiu WC, et al. HbA_1cvariability is strongly associated with the severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes after longer diabetes duration[J]. Front Neurosci, 2019, 13: 458. doi:10.3389/fnins.2019.00458 URL
[33]	Yang Y, Lee EY, Cho JH, et al. Cardiovascular autonomic neuropathy predicts higher HbA_1cvariability in subjects with type 2 diabetes mellitus[J]. Diabetes Metab J, 2018, 42(6): 496-512. doi:10.4093/dmj.2018.0026 URL
[34]	Jang JY, Moon S, Cho S, et al. Visit-to-visit HbA_1cand glucose variability and the risks of macrovascular and microvascular events in the general population[J]. Sci Rep, 2019, 9(1): 1374. doi:10.1038/s41598-018-37834-7 URL
[35]	Shen Y, Zhou J, Shi L, et al. Association between visit-to-visit HbA_1cvariability and the risk of cardiovascular disease in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(1): 125-135. doi:10.1111/dom.14201 URL
[36]	Sheng CS, Tian J, Miao Y, et al. Prognostic significance of long-term HbA_1cvariability for all-cause mortality in the ACCORD trial[J]. Diabetes Care, 2020, 43(6): 1185-1190. doi:10.2337/dc19-2589 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References36

Related Articles11

Recommended Articles

Metrics

Comments

[1]	LU Lin, DAI Yang, WANG Xiaoqun, et al.Several advances of translational research in cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 369-372.
[2]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 349-352.
[3]	XU Qing, SHAO Huiying, CHEN Shuai, QUAN Jinwei, ZHOU Qingfen, WANG Minhui.The tele-nursing education and guidance ameliorate coronary plaque progression in patients with type 2 diabetes mellitus[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 330-333.
[4]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 344-348.
[5]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 373-375.
[6]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 376-380.
[7]	SUN Yan, DAI Danjiao, CHEN Zhiwei, ZHANG Huaqing.Effect of canagliflozin on urinary albumin / creatinine ratio and urinary podocyte-associated protein nephrin in patients with early diabetic kidney disease[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 387-391.
[8]	ZHAO Qingqing, ZHOU Jinxin, PAN Yu, JU Huijun, ZHU Liying, LIU Yang, ZHANG Yifan.Effect of high-dose glucocorticoid on glucose metabolism in rats[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 397-403.
[9]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 418-421.
[10]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(06): 422-426.
[11]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(02): 129-130.